By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer diagnostics firm Dako said today it is collaborating with Genentech on the regulatory submission in the US of two Dako tests as companion diagnostics for Genentech's investigational drug candidate for breast cancer.

The companies will partner on submitting Dako's HercepTest and Her2 FISH pharmDx to the US Food and Drug Administration as companion diagnostics for Genentech's pertuzumab as a treatment for patients with advanced HER2-positive breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.